Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline

Neurology

Volumn 89, Issue 21, 2017, Pages 2176-2186

  Risacher, Shannon L ^a   Anderson, Wesley H ^b   Charil, Arnaud ^b   Castelluccio, Peter F ^a   Shcherbinin, Sergey ^b   Saykin, Andrew J ^a   Schwarz, Adam J ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

13 ITEM SUBSCALE; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL DEMENTIA RATING SUM OF BOX; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA ASSESSMENT; DISEASE ASSOCIATION; DISEASE COURSE; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT QUESTIONNAIRE; HUMAN; IN VIVO STUDY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYMPTOMATOLOGY; ATROPHY; BRAIN; CEREBROSPINAL FLUID; CLASSIFICATION; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; IMAGE PROCESSING; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; REGRESSION ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BRAIN; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS;

EID: 85037680070     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004670     Document Type: Article

References (33)

1. Murray ME, Graff-Radford N, Ross OA, Petersen RC, Duara R, Dickson D. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785-796.
2. Janocko NJ, Brodersen KA, Soto-Ortolaza AI, et al. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 2012;124:681-692.
3. Noh Y, Jeon S, Lee JM, et al. Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs. Neurology 2014;18:1936-1944.
4. Zhang X, Mormino EC, Sun N, et al. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease. Proc Natl Acad Sci USA 2016;113:E6535-E6544.
5. Dickerson BC, Wolk DA. Alzheimer's Disease Neuroimaging I: dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011;82:45-51.
6. Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol 2012;11:868-877.
7. Weiner MW, Aisen PS, Jack CR Jr, et al. The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement 2010;6:202-211.e7.
8. Aisen PS, Petersen RC, Donohue M, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative 2 clinical core: progress and plans. Alzheimers Dement 2015;11:734-739.
9. Beckett LA, Donohue MC, Wang C, et al. The Alzheimer's Disease Neuroimaging Initiative phase 2: increasing the length, breadth, and depth of our understanding. Alzheimers Dement 2015;11:823-831.
10. Franklin EE, Perrin RJ, Vincent B, et al. Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. Alzheimers Dement 2015;11:815-822.
11. Hendrix JA, Finger B, Weiner MW, et al. The worldwide Alzheimer's Disease Neuroimaging Initiative: an update. Alzheimers Dement 2015;11:850-859.
12. Jack CR Jr, Barnes J, Bernstein MA, et al. Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement 2015;11:740-756.
13. Jagust WJ, Landau SM, Koeppe RA, et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET core: 2015. Alzheimers Dement 2015;11:757-771.
14. Jones-Davis DM, Buckholtz N. The impact of the Alzheimer's Disease Neuroimaging Initiative 2: what role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease? Alzheimers Dement 2015;11:860-864.
15. Kang JH, Korecka M, Figurski MJ, et al. The Alzheimer's Disease Neuroimaging Initiative 2 biomarker core: a review of progress and plans. Alzheimers Dement 2015;11: 772-791.
16. Liu E, Luthman J, Cedarbaum JM, et al. Perspective: the Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the private partner scientific board (PPSB). Alzheimers Dement 2015;11:840-849.
17. Saykin AJ, Shen L, Yao X, et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans. Alzheimers Dement 2015;11: 792-814.
18. Toga AW, Crawford KL. The Alzheimer's Disease Neuroimaging Initiative informatics core: a decade in review. Alzheimers Dement 2015;11:832-839.
19. Weiner MW, Veitch DP, Aisen PS, et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 2015;11:865-884.
20. Weiner MW, Veitch DP, Aisen PS, et al. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2015;11:e1-e120.
21. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 2009;65:403-413.
22. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70-77.
23. Crane PK, Carle A, Gibbons LE, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502-516.
24. Gibbons LE, Carle AC, Mackin RS, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517-527.
25. Chen K, Ayutyanont N, Langbaum JB, et al. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011;56:52-60.
26. Migliaccio R, Agosta F, Possin KL, et al. Mapping the progression of atrophy in early- and late-onset Alzheimer's disease. J Alzheimers Dis 2015;46:351-364.
27. Ossenkoppele R, Cohn-Sheehy BI, La Joie R, et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Hum Brain Mapp 2015;36:4421-4437.
28. Frisoni GB, Pievani M, Testa C, et al. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007;130:720-730.
29. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404.
30. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991;82:239-259.
31. Park JY, Na HK, Kim S, et al. Robust identification of Alzheimer's disease subtypes based on cortical atrophy patterns. Sci Rep 2017;7:43270.
32. Dong A, Toledo JB, Honnorat N, et al. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers. Brain 2017;140:735-747.
33. Na HK, Kang DR, Kim S, et al. Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age. Neurobiol Aging 2016; 47:149-156.